Skip to Content

Ultravist Injection Dosage

Generic name: IOPROMIDE 498.72mg in 1mL
Dosage form: injection

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Visually inspect ULTRAVIST for particulate matter and/or discoloration, whenever solution and container permit. Do not administer ULTRAVIST if particulate matter and/or discoloration is observed.
Determine the volume and concentration of ULTRAVIST Injection to be used taking into account factors such as age, body weight, size of the vessel and the rate of blood flow within the vessel; consider also extent of opacification required, structure(s) or area to be examined, disease processes affecting the patient, and equipment and technique to be employed. Specific dose adjustments for age, gender, weight and renal function have not been studied for ULTRAVIST Injection. As with all iodinated contrast agents, lower doses may have less risk. The efficacy of ULTRAVIST Injection below doses recommended has not been established.
The maximum recommended total dose of iodine in adults is 86 grams; a maximum recommended total dose of iodine has not been established for pediatric patients.
Hydrate patients adequately prior to and following the administration of ULTRAVIST [see Warnings and Precautions (5.2)].

Intra-Arterial Procedures

The volume and rate of injection of the contrast agent will vary depending on the injection site and the area being examined. Inject contrast at rates approximately equal to the flow rate in the vessel being injected.

Cerebral Arteriography (300 mg Iodine per mL), Coronary Arteriography and Left Ventriculography (370 mg Iodine per mL), Peripheral Arteriography (300 mg Iodine per mL): see Table 1.
Aortography and Visceral Angiography (370 mg Iodine per mL):
 
Use a volume and rate of contrast injection proportional to the blood flow and related to the vascular and pathological characteristics of the specific vessels being studied. Do not exceed 225 mL as total dose for the procedure.

Table 1: Suggested Single Injection Doses for Adult Intra-Arterial Procedures

Cerebral Arteriography

(300 mg Iodine per mL)

Peripheral Arteriography

(300 mg Iodine per mL)

Coronary Arteriography and Left Ventriculography

(370 mg Iodine per mL)

 
Intra-Arterial Injection Sites

Carotid Arteries

Vertebral Arteries

Aortic Arch Injection (4 vessel study)

3–12 mL

4–12 mL

20–50 mL

-

-

Right Coronary Artery

Left Coronary Artery

Left Ventricle

-

-

3–14 mL

3–14 mL

30–60 mL

 

Subclavian or Femoral Artery

Aortic Bifurcation (distal runoff)

-

5–40 mL

25–50 mL

-

 

Maximum Total Dose

150 mL

250 mL

225 mL

Intravenous Procedures

Peripheral Venography (240 mg Iodine per mL):
 
Inject the minimum volume necessary to visualize satisfactorily the structures under examination. Do not exceed 250 mL as total dose for the procedure.
Contrast Computed Tomography (CT) (300 mg Iodine per mL and 370 mg Iodine per mL) and Excretory Urography (300 mg Iodine per mL): see Table 2.

Table 2: Suggested ULTRAVIST Injection Dosing for Adult Intravenous Contrast Administration

Excretory Urography (300 mg Iodine per mL)

Contrast Computed Tomography (300 mg Iodine per mL)

Contrast Computed Tomography (370 mg Iodine per mL)

Excretory Urography

Approximately 300 mg Iodine per kg body wt. (Adults with normal renal function)

-

-

Head

-

50–200 mL

41–162 mL

Body

Bolus Injection

50–200 mL

41–162 mL

Rapid Infusion

100–200 mL

81–162 mL

Maximum Total Dose

100 mL (30 g iodine)

200 mL (60 g iodine)

162 mL (60 g iodine)

Pediatric Dosing

The recommended dose in children over 2 years of age for the following evaluations is:

Intra-arterial:
 
Cardiac chambers and related arteries (370 mg Iodine per mL):
 
Inject 1 to 2 milliliters per kilogram (mL/kg). Do not exceed 4 mL/kg as total dose.
Intravenous:
 
Contrast Computerized Tomography or Excretory Urography (300 mg Iodine per mL):
 
Inject 1 to 2 mL/kg. Do not exceed 3 mL/kg as total dose.

The safety and efficacy relationships of other doses, concentrations or procedures have not been established [see Use in Specific Populations (8.4) and Clinical Pharmacology (12.3)].

Hide